John Chapin MD

John Chapin, MD is currently an executive medical director and clinical development lead on the hemoglobinopathies programs at CRISPR Therapeutics in Cambridge, MA. John has been working in gene and cell therapy drug development for four years in non-malignant hematology disorders including β-thalassemia, sickle cell disease, hemophilia, and complement-mediated diseases. John received his MD from the University of Vermont Larner College of Medicine and completed his internal medicine residency at Montefiore/Albert Einstein College of Medicine and hematology/oncology fellowship at New York-Presbyterian Hospital. John was an assistant professor of medicine at Weill Cornell Medicine-New York-Presbyterian Hospital associated with the New York Comprehensive Thalassemia Center and the Weill Cornell Regional Hemophilia Center.